To determine the mechanism(s) by which interleukin-I (IL-I) promotes granulopoiesis in vivo, we examined the effect of in vivo administration of IL-la on colony-stimulating factor (CSF) receptor expression on bone marrow cells (BMCs) and whether this directly correlated with progenitor cell responsiveness. Administration of IL-la t o mice induced the upregulation of both granulocyte-macrophage-CSF (GM-CSF) and IL-3 receptors, which reached a maximum 24 hours after IL-la injection on unfractionated BMCs. This upregulation was more pronounced on the progenitor-enriched cell population (lineage-negative [Lin-1). The enhanced GM-CSF and IL-3 receptor expression directly correlated with enhanced IL-3-or GM-CSF-induced growth of colony-forming unitculture (CFU-c) or CFU-mixture (CFU-Mix; colonies containing macrophages, granulocytes, and erythroid cells). In addition, the absolute number of high proliferative potentialcolony-forming cells (HPP-CFC) was increased fivefold. In NTERLEUKIN-1 (IL-1) has potent potentiating activi-
To determine the mechanism(s) by which interleukin-I (IL-I) promotes granulopoiesis in vivo, we examined the effect of in vivo administration of IL-la on colony-stimulating factor (CSF) receptor expression on bone marrow cells (BMCs) and whether this directly correlated with progenitor cell responsiveness. Administration of IL-la t o mice induced the upregulation of both granulocyte-macrophage-CSF (GM-CSF) and IL-3 receptors, which reached a maximum 24 hours after IL-la injection on unfractionated BMCs. This upregulation was more pronounced on the progenitor-enriched cell population (lineage-negative [Lin-1). The enhanced GM-CSF and IL-3 receptor expression directly correlated with enhanced IL-3-or GM-CSF-induced growth of colony-forming unitculture (CFU-c) or CFU-mixture (CFU-Mix; colonies containing macrophages, granulocytes, and erythroid cells). In addition, the absolute number of high proliferative potentialcolony-forming cells (HPP-CFC) was increased fivefold. In NTERLEUKIN-1 (IL-1) has potent potentiating activi-I ties on hematopoietic cell growth both in vitro and in vivo.' Administration of IL-1 in vivo has been shown to increase the number of granulocyte-macrophage colonyforming unit cells (GM-CFU) in the bone marrow (BM) that could lead to enhanced granulop~iesis.~~~ IL-1 also promotes the recovery of myeloid cells after in vivo treatment with sublethal doses of cyclophosphamide and 5-fluorouracil, and also protects mice from the lethal effects of radiation and cycl~phosphamide.~-~ While IL-1 alone cannot promote the proliferation and differentiation of hematopoietic progenitor cells in vitro, it has been shown to act synergistically with the colony-stimulating factors (CS-FS).'O-'~ Because IL-1 has been shown to rapidly induce the production of hematopoietic growth factors (HGFs) such as granulocyte-CSF (G-CSF), granulocyte-macrophage-CSF (GM-CSF), macrophage-CSF (M-CSF), and IL-6 by accessory cells both in vitro and in vivo, it has been proposed that the hematopoietic effects of IL-1 in vivo might be indirectly mediated through these or other cytokines.16-21 For example, it has been shown that IL-1 can upmodulate the expression of its own receptor on BM cells (BMCs) in vivo and not in vitr0,~~9*~ and that this upregulation in vivo is an indirect effect of IL-1 and may be mediated through IL-1-induced G-CSF. 22 We have also shown that HGFs can modulate the expression of CSF receptors on BMCs in vitro.24 Therefore, we investigated whether administration of IL-la in vivo might upregulate CSF receptor expression on BMCs and whether receptor upregulation correlated with enhanced progenitor cell growth. These studies show that administration of IL-la in vivo upregulates the expression of GM-CSF and IL-3 receptors on hematopoietic progenitor cells at least through an indirect mechanism and suggest that this upregulation in combination with the increased serum CSF levels enhances myelopoiesis in vivo.
MATERIALS AND METHODS
Mice. Female C57BL16 mice 8 to 12 weeks of age were obtained from the Animal Production Area at Frederick Cancer Research and Development Center (Frederick, MD). Animal care was provided in accordance with the procedures outlined in the "Guide For Care and Use of Laboratory Animals".24a Mice were maintained in a pathogen-free environment.
Recombinant human IL-la was provided by Dr Peter Lomedico (Hoffman-LaRoche, Nutley, NJ). IL-la was used on weight basis and had a specific activity of 2 x lo7 Ulmg as determined by the thymocyte comitogenic assay. The stock solution was 100 pg/mL in Hanks' Balanced Salt Solution (HBSS) with 0.1% fetal bovine serum (FBS) and was diluted in sterile HBSS before use. The endotoxin content of IL-la was less than 0.02 ng/mg protein by Limulus amebocyte lysate assay. Purified recombinant murine GM-CSF was a gift of Drs T. Boone and I. McNiece (Amgen Corp, Thousand Oaks, CA). Recombinant IL-3 was produced by the transfection of cos-7 cells with a plasmid containing IL-3 cDNA and the supernatant was harvested according to a Cytokines. 2486 Blood, Vol80, No 10 (November 15 The purified recombinant human G-CSF was provided by Dr L. Souza (Amgen). Murine M-CSF was obtained from the conditioned media of L929 cell^,^^^^ and purified recombinant murine IL-3 used for binding assay was purchased from R&D Systems Inc (Minneapolis, MN).
The hybridomas producing the MoAbs RB6-8C5 and RA3-6B2 (CD45; B220) were provided by Dr Robert L. Coffman (DNAX Corp, Palo Alto, CA). Purified rat IgG was purchased from Genex Corp (Gaithersburg, MD). MoAbs Lyt-2 and L3T4 were purchased from Becton Dickinson (Sunnyvale, CA), and MoAb Mac-1 was purchased from Boehringer Mannheim Corp (Indianapolis, IN). An isotype-matched rat IgG was purchased from Cappel (Organon Teknika Corp, West Chester, PA). The anti-IL-1 receptor (anti-IL-1R) antibody (35F5, a rat monoclonal IgG) was prepared at Hoffmann-LaRoche.
Mice (5 to 20 in each group) were treated once with either IL-la in 0.2 mL HBSS or 0.2 mL HBSS alone (vehicle). The antibody (35F5) was administered 6 to 8 hours before the injection of IL-la. The injections were administered intravenously (IV) in the tail veins at different time points before the mice were killed and BMCs harvested. BMCs from control or IL-la-treated mice were separated using lymphocyte separation medium (LSM; Organon Teknika, Durham, NC) and the light-density fraction was obtained. Lineage-negative (Lin-) cells were obtained by further separating the light-density cells using immunomagnetic beads. Briefly, a suspension of light-density BMCs was incubated at 4°C with a cocktail of MoAbs (each at 0.5 kg/106 cells) recognizing antigenic determents for T cells (Lyt-2 and L3T4), pre-B and B cells (B220), macrophages and monocytes (Mac-l), and granulocytes (RB6-8C5). After 30 minutes of incubation, the cells (1 x lo8 cells/mL) were washed and incubated with goat antirat-coated immunomagnetic beads (Dynal AS, Oslo, Norway; 40:l beads to cell) for 30 minutes at 4°C. Cells expressing the linage-specific antigen were removed using a magnetic particle concentrator (Dynal MPC; Dynal) and the remaining Lin-cells were washed and resuspended in Iscove's modified Dulbecco's medium (IMDM). Reanalysis of Lin-cells by flow cytometry showed that approximately 5% of the Lin-cells expressed lineage markers.
Soft agar colony-forming assay. BMCs, unseparated or separated (Lin-), obtained from control or IL-la-treated mice were washed and resuspended in IMDM with 10% FCS, 1% Lglutamine, and antibiotics (complete IMDM). Unseparated or Lin-BMCs were plated in 0.3% Seaplaque agarose (FMC Bioproducts, Rockland, ME) in 35-mm Lux petri dishes (Miles Laboratories, Inc, Naperville, IL). Cultures were supplemented with predetermined optimal doses of GM-CSF (20 ng/mL), G-CSF (20 ng/mL), IL-3 (100 U/mL), or M-CSF (20% L929-supernatant; vol/vol). Dishes were incubated in a fully humidified atmosphere at 37°C in 5% COz for 7 to 10 days before scoring for growth of colony-forming unit-culture (CFU-c). Multipotential colonies, containing granulocyte, erythroid, megakaryocyte, and macrophage lineages (CFU-mixture [CFU-Mix]), and burst-forming units-
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erythroid (BFU-E) were generated in cultures containing optimal concentrations of IL-3, erythropoietin (EPO, 4 U/mL), and hemin. The dishes were incubated as described above for the formation of CFU-c. High proliferative potential-CFU (HPP-CFU) were generated using Lin-cells in a double-layer agar culture system consisting of a 1-mL underlayer of a-modified Eagle's medium (aMEM) with 20% FBS, 0.5% Seaplaque agarose, plus growth factors and a 0.5-mL overlayer of aMEM containing 20% FBS, 0.3% Seaplaque agarose, plus Lin-cells. Lin-cells (2 x 104/dish) were plated in the presence of predetermined optimal concentrations of IL-la (20 ng/mL), IL-3 (100 U/mL), and M-CSF (20% L929-supernatant; vol/vol). The plates were scored for colony formation greater than 0.75 mm in diameter after 14 days of incubation at 37°C in 5% Oz,lO% COz, and 85% Nz.
Lin-cells were incubated in the presence of IL-3 (100 U/mL) or GM-CSF (20 kg/mL) at 37"C, 5 COz, in 96-well microtiter plates at a density of 1 x 105 cells in 100 p,L of complete IMDM. DNA synthesis was assessed with a pulse of 1 KCi 3H-thymidine (6.7 Ci/mmol; New England Nuclear, Boston, MA) for the last 24 hours of the 72-hour incubation period. Radioactivity was determined by liquid scintillation.
Radioiodination of GM-CSF, G-CSF, and IL-3 was performed by a modification of the chloramine-T method, as described previously for IL-3?8 The specific radioactivities of 1251-GM-CSF ranged from 4.0 to 7.0 x 18 cpm/pmol; lZI-IL-3 and 1251-G-CSF both ranged from 1.0 to 2.5 x 1 8 cpm/pmol. There was no significant loss in biologic activity of the cytokines after the iodination procedure. The binding assays were performed by a previously described phthalate oil separation meth0d.2~ BMCs, unseparated or separated, were washed in RPMI 1640 and resuspended in 50 nmol/L glycinehydrochloric acid for 1 minute to release bound ligands. The cells were washed in binding medium (RPMI 1640 containing 2% bovine serum albumin, 20 mmol/L HEPES, and 0.1% sodium azide) before radioiodinated GM-CSF, IL-3, or G-CSF was added to either 2 x lo6 cells for GM-CSF or 8 x 18 cells for I L 3 and G-CSF. After 75 minutes of incubation at 20°C for radioiodinated GM-CSF and 90 minutes at 37°C for both radioiodinated G-CSF and IL-3, cell-bound radioactivity was separated from unbound radioiodinated ligands by centrifugation of the samples through a mixture of dibutyl phthalate and bis(2-ethyl-hexyl) phthalate oil (ratio 1 5 1 ) (Eastman Kodak, Rochester, NY). Specific binding was measured as the difference between counts in the presence and absence of a 50-fold excess of cold competitor. In the equilibrium experiments, increasing concentrations of radioiodinated IL-3 or GM-CSF were added to either 3 X lo6 or 2 x 18 cells for IL-3 or GM-CSF, respectively. To determine the receptor numbers and affinities, the data were analyzed according to the method of Scatchard.3O
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RESULTS
To determine whether the administration of IL-la in vivo affected CSF binding to BMCs, we injected IL-la (1 pg/animal) IV to mice and examined the binding of radioiodinated GM-CSF, IL-3, and G-CSF to BMCs at different times after injection. The specific binding of both lZIL-3 and lZ5GM-CSF to unseparated BM was increased by approximately 50% and loo%, respectively, above control levels, peaking at 24 hours after injection (Fig 1) . The enhanced binding was sustained for 48 hours (Fig 1) dose-dependent with maximal binding observed at 1 kg/ animal of IL-la (data not shown).
In contrast, as previously shown,23 the binding of 1251-G-CSF to unseparated BMCs was rapidly reduced after IL-la administration in vivo. This decrease in binding was detected within 4 hours after injection, with a nadir (60% to 70% reduction) at 12 hours (Fig 1) . G-CSF binding returned to control levels 24 hours after injection and no enhanced binding was observed (Fig 1) .
Because the total BM cellularity was decreased by 30% to 40% within 12 to 24 hours after IL-la injection (from 2.3 ? 0.3 x lo7 to 1.5 ? 0.3 x lo7 cells/femur), this might have contributed to the observed effects on 1251-CSFspecific binding. Using the MoAb RB6-8C5, which recognizes murine granulocytes, with the highest expression present on mature granulocytes (RB6-8C5hi),31 we observed that IL-la induced a rapid reduction in the BM content of RB6-8C5hi cells within 4 hours after injection, with maximal reduction (70% to 80%) by 12 to 24 hours after IL-la administration (Fig 2) . This is in agreement with previous reports describing the rapid IL-la-induced margination of granulocyte^.^^,^^ Expression of G-CSF and GM-CSF receptors are highest on mature myeloid cells compared with immature ~e l l s .~~,~~ Therefore, the decreased specific binding of G-CSF directly correlates with the margination of granulocytes from the BM that express high levels of G-CSF receptor. In contrast, enhanced GM-CSF-and IL-3-specific binding did not correlate with granulocyte margination and occurred at the nadir of BM cellularity, suggesting that increased specific binding was due to increased receptor expression.
To determine whether IL-la treatment affected the numbers of IL-3 and GM-CSF receptors or their affinities, we performed equilibrium binding assays on unseparated BMCs from IL-la-treated or untreated animals. Scatchard analysis showed that murine BMCs express one class of high-affinity IL-3 receptors (kd = 16 pmol/L) and two classes of GM-CSF receptors, one high (kd = 4.2 pmol/L) and one low (kd = 317 pmol/L) (Fig 3A and B) . IL-la administration increased the number of IL-3 receptors from 75 to 120 receptors/cell, and GM-CSF receptors from 55 to 97 high-affinity receptorsfcell and 174 to 266 lowaffinity receptors/cell (Fig 3A and B) . The affinities of the receptors were not changed in IL-la-treated mice compared with controls ( Figs 3A and B) .
The effect of IL-la treatment on IL-3 and GM-CSF binding to Lin-progenitors. Because IL-la-induced upregulation of IL-3 and GM-CSF receptors on unseparated BMCs was maximal at the time when mature myeloid cells were dramatically reduced, we examined if the receptor upregulation occurred on hematopoietic progenitor cells. Therefore, GM-CSF-and IL-3-specific binding was determined on an enriched progenitor population 24 hours after IL-la (1 kg/animal) administration in vivo. Using the combination of light-density and immunomagnetic bead separations to remove cells that express lineage-specific antigens for B and T lymphocytes and monocytes, macrophages, and granulocytes, we obtained a population of BMCs termed Lin-cells, representing approximately 5% of the total BM population. The Lin-population is enriched for multipotent (CFU-granulocyte, erythroid, monocyte, megakaryocyte [CFU-GEMM] and CFU-Mix) and pluripotent hematopoietic progenitors (long-term BM reconstituting cells). 34 In single cell assays, approximately 1 in 5 cells will proliferate under optimal conditions (J.R. Keller, unpublished observations). IL-la administration upregulated the specific binding of IL-3 and GM-CSF 2.7-and 3.5-fold, respectively, on Lin-cells as compared with Lin-cells from vehicle-treated mice (Table 1 ). This enhancement of IL-3- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From of IL-la and BMCs were processed 24 hours after the injections as described in Materials and Methods. Specific 1251-GM-CSF and lZ51-lL-3 were determined by adding various concentrations of radioiodinated cytokines alone or in the presence of 50-fold excess of unlabeled cytokines. Each point is the mean of duplicate determinations from which nonspecific binding was subtracted.
and GM-CSF-specific binding was greater than that observed on unseparated BMCs. Finally, IL-la treatment had no significant effect on G-CSF-specific binding on Lincells (data not shown).
Thus, administration of IL-la in vivo results in increased specific binding of radioiodinated IL-3 and GM-CSF on a highly enriched progenitor cell population, whereas G-CSF binding was not increased 24 hours after IL-la injection.
The effect of IL-la in vivo on the proliferation and differentiation of unseparated and Lin-BMCs. To determine if the IL-la-induced upregulation of GM-CSF-and IL-3-specific binding on BMCs correlated with enhanced progenitor cell growth and differentiation, we examined the BM cellularity and colony formation of unseparated and Lin-BMCs incubated with different cytokines in vitro after IL-la (1 pg/animal) treatment in vivo to determine the total number of CFU-c per femur. The total number of GM-CSF-responsive progenitors per femur 24 hours after IL-la treatment was increased 35%, whereas no significant effect on IL-3-responsive CFU-c was observed (Fig 4A) . In contrast, we observed a consistent decrease (35%) in progenitors responsive to G-CSF in vitro after IL-la in vivo, which was not statistically significant compared with control animals (Fig 4A) .
In comparison, the total number of GM-CSF-and IL-3-responsive CFU-c in the Lin-cell population, an enriched progenitor cell population, from IL-la-treated animals was greatly enhanced compared with Lin-cells from control animals (2.2-fold for GM-CSF and threefold for IL-3; Fig 4B) . No significant difference between IL-latreated and control animals was observed in total numbers of G-CSF-responsive progenitors in the Lin-population (Fig 4B) .
In contrast to the reduction in total BM cellularity observed in mice injected with IL-la, the number of cells within the Lin-cell population did not significantly change in IL-la-treated animals compared with controls (Table 2) . Further, examination of Jenner Giemsa-stained cytocentri- BMCs were harvested from mice pretreated with IL-la or vehicle and the numbers were determined by using a hemocytometer. Lin-cells were obtained by immunomagnetic bead separation as described in Materials and Methods and Table 1 . The results are presented as the total numbers cells per femur and are the mean 2 SD of five separate experiments.
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*Normal mice were injected with IL-lo! (1 kg/animal) or vehicle and BMCs were harvested 24 hours after the injections.
fuged slides of Lin-cells from IL-la-treated animals and control animals did not show any morphologic differences between the populations (data not shown). The constitutive proliferation of Lin-cells from IL-la-treated mice measured in 3H-thymidine incorporation assays was the same as the control animals ( Table 3 ). In addition, Lin-cells from IL-la-treated mice showed approximately a twofold and threefold increase in IL-3-and GM-CSF-induced proliferation, respectively, compared with cells from control mice (Table 3) . tLin-cells were obtained from mice treated with IL-la (1 wglanimal) or vehicle 24 hours before harvest. Lin-cells were obtained as described in Table 1 and Materials and Methods. The cells (1 x I O 5 cells/well) were plated in liquid culture with or without cytokines and pulsed with 3H-thymidine for 24 hours, as described in Materials and Methods.
SCytokines were used in optimal doses as outlined in Materials and Methods.
Thus, the growth and proliferation of BMCs in response to CSFs in vitro directly correlated with the modulation of lzSI-CSF-specific binding to unseparated and Lin-BMCs from IL-la-treated animals.
The effect of IL-la in vivo on multipotentialprogenitors in the BM. To determine whether receptor upmodulation of IL-3 (Fig 3) and IL-1 receptorsz2 after IL-la-treatment in vivo affected the growth of primitive hematopoietic progenitors, we examined the growth of HPP-colony-forming cells (HPP-CFC); CFU-Mix, which contains myeloid and erythroid cells; and BFU-E. HPP-CFC are defined by their ability to form large colonies ( > 0.5 mm in diameter) in the presence of IL-1, IL-3, and M-CSF, whereas CFU-Mix and BFU-E are induced by IL-3 and EPO. The absolute number of HPP-CFC in Lin-cells from mice injected with IL-la was sixfold to sevenfold greater than the number obtained from vehicle-treated mice (Fig 5) . Furthermore, the formation of immature multilineage progenitors, CFUMix, were increased approximately twofold 24 hours after IL-la administration in vivo (Fig 5) . In contrast, the formation of BFU-E in the Lin-population was the same in IL-la-treated animals and control animals (Fig 5) . Thus, IL-la in vivo also enhanced the number of highproliferative and multilineage progenitors in the Lin-cell population, while the number of more mature erythroid (BFU-E) progenitors was the same in IL-la-treated animals and control animals.
The effect of anti-IL-IR antibody on the IL-la-induced upregulation of CSF binding on BMCs in vivo. To determine whether IL-la-induced IL-3 and GM-CSF receptor upmodulation on BMCs was direct or indirectly mediated, mice were injected with 35F5 antibody in vivo before treatment with IL-la. The 35F5 antibody has been shown to selectively block IL-1 binding to type I IL-1R found on fibroblasts, endothelial cells, and T cells, but not the type I1 IL-lR expressed on macrophages, granulocytes, and B ~e l l s .~~,~~ In addition, we have previously shown that the administration of 35F5 before IL-la treatment blocked the upregulation of type I1 IL-1R (80%) on BMCs in vivo.z2 Mice were injected with 100 pg of 35F5 antibody or control IgG 6 hours before the injection of 300 ng of IL-la.
GM-CSF-and IL-3-specific binding was assessed 24 hours after IL-la injection. As before, the administration of IL-1 in vivo increased 1251-GM-CSF-specific binding on BMC after 24 hours (Fig 1) . The administration of 35F5 antibody blocked the IL-la-induced upregulation of GM-CSF ( Fig  6) and IL-3 (data not shown) binding to BMCs, whereas the administration of control antibody had no effect on IL-lainduced upregulation of GM-CSF and IL-3 binding (data not shown). IL-la in vivo directly correlates with the release of CSFs by accessory cells and enhanced progenitor cell growth.
DISCUSSION
It was possible that the observed enhanced binding of IL-3 and GM-CSF to BMCs might have been due to the effective enrichment of cells already expressing CSF receptors because BM cellularity was reduced after IL-la administration. However, the majority of cells marginating from the BM are mature granulocytes and we and others have previously shown that most of the GM-CSF-specific binding in whole BM is on RB6-8CSh1 granulocyte^?^,^^ In addition, it has been shown that IL-3-specific binding occurs on more mature myeloid cells in the Furthermore, IL-3-and GM-CSF-specific binding was more dramatically increased on purified Lin-cells after IL-la administration, indicating that the increased binding occurred on immature myeloid progenitors. This observation is in contrast to a report by Shieh et a1 in which no effect on GM-CSF-specific binding was detected on whole BM after the administration of IL-1 in vivo.23 It is possible that the dose of 200 nglanimal used in their study was too low to enhance GM-CSF binding because the upregulation of GM-CSF receptors by IL-la in vivo is dose-dependent with the maximum response observed at 1 pg/animal. Also, because Shieh et a P looked at the effects on whole BM, some upregulation on progenitors might have occurred but went undetected in the whole population. Finally, whereas their studies have used IL-1P, we have exclusively used IL-la in vivo, which could account for the observed differences.
In contrast to the upregulation of GM-CSF and IL-3 receptor expression after IL-la administration in vivo, and in agreement with the studies by Shieh et al,23 we observed that IL-la in vivo rapidly and transiently reduced the binding of radioiodinated G-CSF to unseparated BMCs. However, the reduction correlated with the IL-la-induced migration out of the marrow of mature granulocytes (RB6-8C5h1 cells) that express high levels of G-CSF receptors.33 This indicates that the IL-la-induced reduction in G-CSF binding on unseparated BMCs could be explained by the egress from the marrow of receptor-positive mature myeloid cells. In support of this, the binding of G-CSF to purified Lin-progenitors was unchanged after IL-la in vivo.
The magnitude of IL-3 and GM-CSF receptor upregulation on purified Lin-BMCs after IL-la administration in vivo directly correlated with the increased number of IL-3-and GM-CSF-responsive CFU-c, as well as proliferation in 3H-thymidine assays. IL-la-induced upregulation of IL-3 binding on Lin-cells also correlated with a dramatic increase in the growth of more primitive progenitors such as HPP-CFC in vitro. Because IL-1 and IL-3 can promote the growth of HPP-CFC in vitro, the increased numbers of HPP-CFC in IL-la-treated mice correlated with the observed increase in IL-3 receptor expression and IL-1 receptor expression22 after the in vivo administration of IL-1. Therefore, the upregulation of both IL-3 and IL-1 binding on progenitor cells could contribute to the enhanced formation of HPP-CFC in IL-la-treated animals.
The anti-IL-1R antibody (35F5) has been shown to inhibit the binding of IL-1 to type I IL-1R expressed on T cells, fibroblasts, and epithelial cells. 35 In addition, this antibody has been shown to inhibit IL-1-induced induction of CSF in vitro and in vivo.21 Because 35F5 blocked the IL-la-induced upregulation of GM-CSF and IL-3 binding to BMCs, this suggested that CSF receptor upregulation was indirectly mediated possibly through the action of endogenously induced HGF. We have also shown that anti-type I IL-1R antibody could similarly block the upregulation of IL-1 receptor expression after IL-la administration in viv0.2~ In addition, we have shown that GM-CSF receptor expression can be upregulated on Lin-cells by IL-6, G-CSF, and IL-3 in vitro, and that IL-3 receptor expression can be upmodulated by IL-6 and G-CSF.24 In contrast, G-CSF receptor expression on Lin-cells in vitro is only increased by IL-3.24 Because IL-1 has been shown to induce the production of IL-6 and G-CSF and not IL-3 in vivo, our in vitro results directly correlate with the observed upregulation of GM-CSF and IL-3 but not G-CSF on Lincells from IL-la-treated animals.
We 
